Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, nandrolone decanoate treatment in rats caused persistent diestrus and altered steroid receptor expression and sex hormones, especially at higher doses, with partial reversibility at lower doses over time.

This case report describes a male patient with aromatase deficiency, revealing that a c.628G>A mutation can lead to varied clinical features, such as low bone mass and normal metabolic profiles.

In this study, analysis of FDA data revealed a substantial risk of dermatologic adverse events with aromatase inhibitors, especially anastrozole and exemestane, highlighting the importance of dermatologic monitoring during such therapies.

This study suggests that the testosterone analogs 7α-Methyltestosterone and 7α-Ethyltestosterone may offer promising androgenic, progestogenic, and anabolic properties for development as male contraceptives.

This review discusses differences in ERβ signaling between rodents and humans and reports no new clinical results; the authors highlight the need for further research in humans before using ERβ agonists clinically.

This study suggests that inhibitors of steroidogenic enzymes may have therapeutic potential for certain behavioral disorders linked to dopaminergic hyperfunction, despite concerns about their endocrine impacts.

This review explores androgen metabolism in the skin, highlighting enzyme localization and potential implications for treating androgen-dependent skin conditions, but it reports no new clinical results.

This review discusses the various evidence-based and potential applications of metformin in treating and preventing symptoms and complications associated with polycystic ovary syndrome but reports no new clinical results.

The NAMS 2014 recommendations guide healthcare providers on treating health issues in midlife women, emphasizing individualized care and informed decision-making.

This review discusses the isolation, structure, and bioactivity of lignans and neolignans from 2016 to mid-2018, reporting no new clinical results but highlighting their potential protective properties against diseases such as cancer and neurodegeneration.

This review discusses phytotherapy options for managing benign prostatic hyperplasia, noting some herbal agents show promise in trials for mild-moderate symptoms but more evidence is needed for others.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.

This review discusses the role of cholesterol homeostasis in hair follicle biology and its potential connections to various hair disorders, but it reports no new findings.

This study found that inhibiting the enzyme 5α-reductase with finasteride counteracted stress-induced prepulse inhibition deficits in socially isolated rats by altering neuroactive steroid concentrations in the brain.

This review discusses various targets for treating prostate cancer and benign prostatic hyperplasia and reports on recent studies of new compounds and 5α-reductase inhibitors, but provides no new experimental results.

This study explored the optimization of phytochemicals from Alstonia boonei to develop potential 5-alpha reductase inhibitors for Benign Prostatic Hyperplasia, finding promising analogs with enhanced binding affinity and stability compared to Finasteride, warranting further experimental validation.

This review examines the potential of apigenin and ellagic acid as adjunct or alternative treatments for PCOS, but reports no new clinical results and highlights the need for further trials to confirm their efficacy and optimize dosing and delivery.

This review discusses 46,XY disorders of sex development caused by defects in androgen production and highlights the need for long-term care from experienced multidisciplinary teams, but it reports no new clinical findings.

This review discusses the role of androgen therapy and neurosteroids in cerebrovascular health, highlighting the potential risks and benefits and the importance of pharmacogenetic testing, but reports no new experimental results.

This review summarizes factors involved in polycystic ovary syndrome pathogenesis and management, highlights commonly prescribed and repurposed medications, and calls for well-designed clinical trials to evaluate these treatments further.

This review provides an analysis of the physiological and pathological aspects of polycystic ovary syndrome, emphasizing endocrine, metabolic, and inflammatory dimensions, but reports no new clinical results.

This abstract provides a comprehensive overview of enzyme classification, function, and interaction with drugs, but does not present new research findings.

This review discusses the integration of omics analyses in androgenetic alopecia research, reporting no new clinical results but suggesting that collaborative multi-omics studies may enhance understanding of AGA's pathomechanisms.

This source reviews recent research on Ginkgo biloba, highlighting its medicinal benefits due to compounds in the leaves and concerns over toxic alkylphenols in seeds. It also discusses patents for its food production uses and ongoing studies on toxicity and drug interactions.

People with hair loss have more androgen receptors and enzymes in certain follicles, with men and women showing different patterns.

This study found that 17α‐estradiol increases aromatase activity in female hair follicles, which may explain its beneficial effects in treating androgenetic alopecia.

This review discusses management strategies for sexual side effects of aromatase inhibitors in postmenopausal breast cancer patients and reports no original clinical findings.

In this study, genetic variation in the CYP19A1 gene, particularly the common rs4646 C allele, was associated with an increased risk of female pattern hair loss, especially in women under 40.

This study found that dexamethasone significantly reduced ERα mRNA levels and increased aromatase mRNA and activity in cultured human hair follicle dermal papilla cells, suggesting a glucocorticoid-dependent mechanism for estradiol action.

This study found that the steroidal aromatase inhibitor exemestane stimulated proliferation of human osteoblast cells, suggesting both androgen receptor-dependent and independent pathways are involved.